BMS, Innate Pharma share interim data
PRINCETON, N.J. & MARSEILLE, France—An interim efficacy analysis from a Phase 1/2 study combining lirilumab and Opdivo (nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck (SCCHN) was reported recently by Bristol-Myers Squibb and Innate Pharma SA. The objective response rate (ORR) among 29 evaluable patients with SCCHN was 24 percent, and 17 percent of the evaluable patients showed deep responses with tumor burden reduction of more than 80 percent. The analysis also included exploratory biomarker analyses of patient response by level of PD-L1 expression; early signals of enhanced clinical benefit were seen in PD-L1- positive tumors, with an ORR of 41 percent in patients with >1% PD-L1 expression. The data from this analysis are the first demonstrating potential efficacy of combining an anti-KIR antibody with an anti-PD-1 therapy.